Benicar, also known as olmesartan medoxomil, is a prescription drug created by pharmaceutical company Daiichi Sankyo. Released on the market in 2002, the drug has been used to treat high blood pressure in both adults and children over six years old. Benicar treats high blood pressure by preventing the narrowing of blood vessels, which lowers blood pressure and improves blood flow.

Despite the manufacturers' claims that Benicar is safer and more effective than other high-blood pressure medications available on the market, it has been reported to cause severe side effects that are not seen with the use of other drugs in its class.

Harmful Side Effects
It took over ten years for the FDA to issue warnings about the severe side effects of Benicar use, including intestinal damage, malnourishment, and severe weight loss.

Other harmful side effects not advertised by Daiichi Sankyo include:

  • Dehydration
  • Chronic diarrhea
  • Nausea
  • Skin Rashes
  • Vomiting

Many patients who have experienced these symptoms have required medical attention and, in some cases, hospitalization. Those that have suffered from gastrointestinal complications because of Benicar use often do not realize that the drug is to blame for their conditions, and may experience symptoms for years before their doctor properly diagnoses them.

Your Legal Options
It is estimated that Daiichi Sankyo spent nearly $1 billion promoting Benicar from 2002 to 2008. Today, many Benicar users are filing lawsuits against the manufacturer. Complaints include putting consumers at risk by manufacturing a defective and dangerous product and marketing it to the public without properly warning users.

The first Benicar lawsuits were filed in early 2014. If you have used Benicar and experienced serious gastrointestinal side effects, you might be eligible for compensation for expensive medical bills, lost income from time off of work, and more. Do not hesitate to contact Brayton Purcell LLP today for a free initial consultation to find out more about your legal options.